Compositions containing vitamin B5 for improving respiratory health and treating or preventing respiratory diseases, pharmaceutical compositions containing the same for treating or preventing respiratory diseases, and health functional food compositions containing the same for improving respiratory health or respiratory diseases.

Abstract

This invention relates to a composition containing vitamin B5 for improving respiratory health and treating or preventing respiratory diseases, a pharmaceutical composition containing the same for treating or preventing respiratory diseases, and a health functional food composition containing the same for improving respiratory health or respiratory diseases.

Description

Technical Field

[0004] , , , , ,

[0006] , , ,

[0007] , , , , , , , ,

[0005]

[0001] The present invention relates to a composition for improving respiratory health and treating or preventing respiratory diseases, which contains vitamin B5, a pharmaceutical composition for treating or preventing respiratory diseases containing the same, and a health functional food composition for improving respiratory health or respiratory diseases containing the same.

Background Art

[0002] In the case of health functional foods, it is common to take them orally in the form of capsules, purification, etc. However, when health functional foods are taken orally, there is a problem that when absorbed by the body, decomposition or excretion of the material occurs through metabolism and decomposition.

[0003] On the other hand, vitamin B5 has improvement effects on various aspects such as preventing hair loss, relieving stress, relieving depression, improving immunity, and preventing anemia when taken orally. The recommended daily intake for adults is 10 mg, but the required daily oral dosage for humans is 100 - 1000 mg, and there is a disadvantage that a high volume intake is required. Except for oral administration of vitamin B5, research on other administration methods is negligible.

Summary of the Invention

Problems to be Solved by the Invention

[0004] In order to solve the above problems, the present invention aims to provide a composition containing vitamin B5 as an active ingredient, which can improve respiratory health and have a respiratory protection effect with a small amount, and also have an improvement, prevention, and treatment effect on respiratory diseases.

[0005]

[0006] However, the problems to be solved by the present invention are not limited to those mentioned above, and for other problems not mentioned, they will be clearly understood by those skilled in the art in the relevant field from the following description.

Means for Solving the Problems

[0007] According to one embodiment of the present invention, a composition for improving respiratory health and treating or preventing respiratory diseases is provided, which contains vitamin B5 as an active ingredient.

[0008] According to another embodiment of the present invention, a pharmaceutical composition for the treatment or prevention of respiratory diseases is provided, comprising a composition for improving respiratory health and treating or preventing respiratory diseases according to one embodiment of the present invention.

[0009] According to yet another embodiment of the present invention, a health functional food composition for improving respiratory health or respiratory diseases is provided, comprising a composition for improving respiratory health and treating or preventing respiratory diseases according to one embodiment of the present invention. [Effects of the Invention]

[0010] The composition of the present invention can reduce the total cell count, inflammatory cells, and inflammatory cytokines in the bronchopulmonary lavage fluid, thereby improving respiratory health, alleviating respiratory diseases including respiratory inflammation, allergies, and asthma, and protecting against respiratory damage caused by fine dust and pathogens. Furthermore, the present invention can achieve the above-mentioned respiratory health improvement and respiratory disease treatment or preventive effects even with smaller doses than when administered orally, when administered by inhalation.

[0011]

[0012] The effects of the present invention are not limited to those described above, but should be understood to include all effects that can be inferred from the detailed description of the present invention or the configuration of the invention as described in the claims. [Brief explanation of the drawing]

[0013] [Figure 1] This shows the results of evaluating the total number of cells in bronchopulmonary lavage fluid using examples and comparative examples of the present invention.

[0014] [Figure 2]This shows the results of evaluating the inhibitory effect of the present invention on inflammatory cells (neutrophils) in bronchopulmonary lavage fluid using examples and comparative examples.

[0015] [Figure 3] This shows the results of confirming the number of neutrophils in bronchopulmonary lavage fluid using immunofluorescence staining (FACS) indicators in the examples and comparative examples of the present invention.

[0016] [Figure 4] This shows the results of confirming the reduction of the inflammatory factor cytokine IL-6 in bronchopulmonary lavage fluid using the examples and comparative examples of the present invention. [Modes for carrying out the invention]

[0017] The embodiments will be described in detail below with reference to the attached drawings. However, various modifications can be made to the embodiments, and the scope of the patent application is not limited or restricted by these embodiments. All modifications, equivalents, or substitutes to the embodiments should be understood to be included in the scope of the patent.

[0018] The terms used in the embodiments are for illustrative purposes only and should not be construed as limiting. Singular expressions include plural expressions unless the context clearly indicates otherwise. In this specification, terms such as “includes” or “has” should be understood as specifying the presence of features, numbers, steps, operations, components, parts, or combinations thereof described in the specification, and not as preemptively excluding the presence or possibility of adding one or more other features, numbers, steps, operations, components, parts, or combinations thereof.

[0019] Unless otherwise defined, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which the embodiments belong. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with the context of the related art and should not be interpreted in an idealized or overly formal sense unless clearly defined in this application.

[0020] In addition, when describing with reference to the accompanying drawings, regardless of the reference numerals, the same components are denoted by the same reference numerals, and duplicate descriptions thereof are omitted. When describing the embodiments, if it is determined that a specific description of related known technologies may obscure the gist of the embodiments, the detailed description thereof is omitted.

[0021] Furthermore, when describing the components of the embodiments, terms such as first, second, A, B, (a), (b), etc. can be used. These terms are for distinguishing the components from other components, and the essence, order, or sequence of the corresponding components are not limited by these terms.

[0022] Components including functions common to the components included in any of the embodiments are described using the same names in other embodiments. Unless otherwise stated, the descriptions given in any of the embodiments are applicable to other embodiments, and specific descriptions within the overlapping scope are omitted.

[0023] Throughout the specification, when a part mentions that a certain component "includes", this means that it does not exclude other components and may further include other components.

[0024]

[0025] [[ID= Vitamin B5, as mentioned above, is a water-soluble vitamin belonging to the vitamin B complex. It is an essential substance for producing collagen, which makes up skin and hair, and it helps create beautiful skin and healthy hair by breaking down lipids and preventing oily skin. Vitamin B5 can also have anti-inflammatory effects, as well as preventing hair loss, relieving stress, alleviating depression, improving immunity, and preventing anemia.

[0027] In the present invention, the terms “improvement” or “treatment” may mean any action by which the administration of the composition improves or beneficially alters the symptoms of respiratory health or disease. Furthermore, the term “prevention” may mean any action by which the administration of the composition of the present invention suppresses or delays the onset, spread, or recurrence of respiratory-related diseases.

[0028] In this invention, the term "respiratory system" refers to the trachea, which is capable of inhaling oxygen from the air and expelling carbon dioxide produced as a result of energy metabolism, and can mean the airways, bronchi, lungs, etc. When the cells or tissues of such respiratory organs are subjected to some kind of invasion that causes a qualitative change, inflammation can occur in the body's defense response process to repair or regenerate the damaged area, for example, due to bacteria, viruses, smoking, air pollution, etc. This series of reactions includes local blood vessels, various tissue cells in body fluids, immune-participating cells, etc.

[0029] In this invention, the term "respiratory disease" means a negative symptom that may occur in the respiratory system. The respiratory disease is not limited to any disease that manifests as a result of inflammation in the respiratory system, but examples include one or more diseases selected from the group consisting of allergies, bronchitis, sinusitis, lower respiratory tract infections, bronchiolitis, asthma, chronic obstructive pulmonary disease, rhinitis, pneumonia, emphysema, bronchiectasis, pulmonary fibrosis, cough, sputum, pharyngitis, tonsillitis, and laryngitis.

[0030] Furthermore, the compositions of the present invention may also have an improving effect on respiratory health deterioration that may occur due to external factors such as fine dust, pathogens, and viruses. In the present invention, "improvement of respiratory health" means reducing the intensity and frequency of one or more respiratory symptoms selected from the group consisting of swollen tonsils, swollen throat, cough, sneezing, phlegm production, sore throat, nasal congestion, and hoarseness, eliminating respiratory symptoms, or preventing respiratory symptoms.

[0031] A composition for improving respiratory health and treating or preventing respiratory diseases according to one embodiment of the present invention can be used for all animals, including humans who have developed or are at risk of developing respiratory diseases. The animals may be, but are not limited to, humans, cattle, horses, sheep, pigs, goats, camels, antelopes, dogs, cats, mice, and other animals that require treatment for similar symptoms.

[0032]

[0033] A composition for improving respiratory health and treating or preventing respiratory diseases according to one embodiment of the present invention may be applied to inflammation by inhalation or spraying.

[0034] In this case, the inhalation or spray may be applied to the oral cavity or nasal cavity. Preferably, inhalation or spraying through the oral cavity is highly effective as it allows for direct application of fine droplets to the area around the throat in the mouth, where respiratory inflammation is most prevalent. By being administered by inhalation or spraying, the present invention avoids metabolism (decomposition) in the body, is absorbed immediately, and can improve and treat respiratory inflammation with a smaller amount.

[0035] The inhalation or spraying may be applied by an ultrasonic, spray, or fogging device. In this case, the respiratory health improvement and treatment or prevention of respiratory diseases composition may be administered to the user from the device by means of heating, ultrasonic, surface waves, etc., but is not limited to the methods described. In particular, when administered by heating, the delivery efficiency and speed of the respiratory health improvement and treatment or prevention of respiratory diseases composition of the present invention can be increased.

[0036]

[0037] In a composition for improving respiratory health and treating or preventing respiratory diseases according to one embodiment of the present invention, the composition for improving respiratory health and treating or preventing respiratory diseases can be formulated in an inhalable form according to a conventional method and used.

[0038] For example, the aforementioned composition for improving respiratory health and treating or preventing respiratory diseases may be a liquid and may be sprayable. When the present invention is a liquid, it can be aerosolized and sprayed by methods such as heating, ultrasound, or surface waves.

[0039]

[0040] In a composition for improving respiratory health and treating or preventing respiratory diseases according to one embodiment of the present invention, the dosage may be 1 mg / kg to 30 mg / kg.

[0041] While the daily oral dose of vitamin B5 for humans can be considered high at 50 mg / kg or more, this invention allows for superior improvement of respiratory inflammation and therapeutic effects even at lower doses through inhalation administration.

[0042] The present invention can have respiratory health improvement and therapeutic or preventive effects on respiratory diseases within the above numerical range of dosage. Preferably, the dosage of the composition for respiratory health improvement and therapeutic or preventive effects on respiratory diseases may be 1 mg / kg to 30 mg / kg, preferably 5 mg / kg to 28 mg / kg, and more preferably 8 mg / kg to 28 mg / kg. If the dosage of the present invention is below the above numerical range, the improvement and therapeutic effects on respiratory diseases may be minimal. On the other hand, even if the dosage of the present invention exceeds the above numerical range, the improvement, therapeutic, and preventive effects on respiratory diseases will not be further improved.

[0043]

[0044] The dosage of a composition for improving respiratory health and treating or preventing respiratory diseases according to one embodiment of the present invention can be achieved, for example, by adjusting the concentration, administration time, and frequency of administration of the composition.

[0045] For example, in a composition for improving respiratory health and treating or preventing respiratory diseases according to one embodiment of the present invention, the concentration of vitamin B5 may be 2% to 30% by weight, preferably 5% to 25% by weight, and more preferably 10% to 20% by weight, based on the total weight of the composition for improving respiratory health and treating or preventing respiratory diseases, and the administration time may be 5 to 60 minutes. However, the method for achieving the administration volume is not limited to the examples described.

[0046]

[0047] According to one embodiment of the present invention, a health functional food composition for improving respiratory health or respiratory diseases can be provided, which includes the composition for improving respiratory health and treating or preventing respiratory diseases.

[0048] The aforementioned health functional food composition refers to a food manufactured and processed using raw materials and ingredients that have beneficial functional properties for the human body, as defined in Act No. 6727 of the Act on Health Functional Foods. "Functionality" means that the food is taken for the purpose of regulating nutrients in relation to the structure and function of the human body, or for obtaining beneficial effects for health purposes, such as physiological effects.

[0049]

[0050] According to one embodiment of the present invention, a pharmaceutical composition for the treatment or prevention of respiratory diseases can be provided, which includes a composition for improving respiratory health and for the treatment or prevention of respiratory diseases.

[0051] A pharmaceutical composition means one manufactured for the purpose of preventing or treating a disease. The compositions for improving respiratory health and treating or preventing respiratory diseases may be used alone, in combination with other pharmaceutically active compounds that exert preventive and therapeutic effects on respiratory inflammatory diseases, or in appropriate combinations.

[0052]

[0053] According to one embodiment of the present invention, a method for treating or preventing a respiratory disease can be provided, comprising administering the pharmaceutical composition for treating or preventing the respiratory disease to an individual. The individual can mean any animal, including humans, and may be, but is not limited to, humans, cattle, horses, sheep, pigs, goats, camels, antelopes, dogs, cats, mice, and the like.

[0054] According to one embodiment of the present invention, the pharmaceutical composition for the treatment or prevention of respiratory diseases can be provided for use in the treatment or prevention of respiratory diseases.

[0055]

[0056] The present invention will be described in more detail below with reference to embodiments, but the present invention is not limited to the embodiments described below.

[0057]

[0058] 1. Manufacture of inhalation compositions for improving and treating respiratory inflammation.

[0059] 25, 100, and 200 g of vitamin B5 (Pantothenic Acid, 0412678, DSM, UK) were measured out and placed in 1-liter beakers. 700 ml of primary distilled water was added to each beaker, and the mixture was stirred for 15 minutes. After adding 1,000 ml of primary distilled water to the total volume, the mixture was stirred for 15 minutes to produce inhaled administration compositions for improving and treating respiratory inflammation containing 2.5%, 10%, and 20% concentrations of vitamin B5.

[0060]

[0061] 2. Manufacture of oral compositions for improving and treating respiratory inflammation

[0062] To prepare low, medium, and high doses for oral administration of vitamin B5 (Pantothenic Acid, 0412678, DSM, UK), 150, 300, and 600 mg of vitamin B5 were measured and placed in 250 ml glass bottles. 100 ml of primary distilled water was added to each 250 ml glass bottle, and the mixture was stirred for 15 minutes to prepare oral compositions for improving and treating respiratory inflammation. The test substances prepared according to their respective volumes were administered orally at a dose rate of 10 ml / kg using a gastric tube.

[0063]

[0064] 3. Production of a respiratory injury model administered with a composition for improving and treating respiratory inflammation.

[0065] (1) Laboratory animals

[0066] The experimental animals were Balb / c mice (male, 6 weeks old, 15-17g body weight) purchased from Coretech after approval from the Animal Experiment Ethics Committee (IACUC). They were purified for one week in the KT&G Bio Efficacy Evaluation Center's breeding room (temperature 23±2℃, humidity 50±10%, light-dark cycle 12 hours) before being used in the experiments.

[0067]

[0068] (2) Preparation of test substances for inducing respiratory injury models

[0069] A PM10D mixture was prepared by diluting 3 mg / mL of fine dust particles [Particulate Matter 10 (hereinafter PM10), ERM-CZ120, Sigma Aldrich, St. Louis, MO, USA] and 0.6 mg / mL of diesel combustion dust [Diesel Particulate Matter (hereinafter DEP), NIST-2975, Sigma Aldrich, St. Louis, MO, USA] in 1% aluminum (aluminium hydroxide, 239186, Sigma Aldrich, USA).

[0070]

[0071] (3) Creation of a respiratory injury model

[0072] After temporarily anesthetizing experimental animals with isoflurane, a respiratory injury and inflammation model was created by administering 50 μl each of PM10D through the nose and mouth (100 μl total) three times (on days 3, 6, and 9 after administration of the test substance).

[0073]

[0074] (4) Production of respiratory injury models administered with compositions for improving and treating respiratory inflammation.

[0075] Each group consisted of 5-6 animals. Comparative Examples 1 and 2 included a normal group of animals that received no treatment, a respiratory injury inflammation model group that received PM10D followed by inhalation of purified water (60 minutes / day) (induced group), and oral administration groups for Comparative Examples 3-5. In Examples 1-8, after treatment with PM10D, 2.5%, 10%, and 20% vitamin B5 were administered by inhalation at different doses (mg / kg) for 10 days, with the administration time adjusted, to compare the effect on inflammation. The inhalation administration was performed using a mist generator. The dose was calculated using the formula derived from prior literature (Alexander et al., Inhal Toxicol. 2008 Oct;20(13):1179-89.) based on the aerosol exposure (mg / L).

[0076]

[0077] [Table 1]

[0078]

[0079] 4. Experimental Example 1: Evaluation of total cell count in bronchopulmonary lavage fluid

[0080] The total number of cells in the bronchoalveolar lavage fluid (BALF) of Examples 1-8 and Comparative Examples 1-5 was investigated. The investigation method was as follows:

[0081] In Examples 1-8 and Comparative Examples 1-5, experimental animals were anesthetized with isoflurane 11 days after the end of administration, blood was collected, the airway was exposed, and a syringe containing 1 mL of phosphate buffer solution (Gibco, UK) was inserted into the bronchus and secured with suture. Bronchoalveolar lavage fluid was obtained by repeating the process three times using phosphate buffer solution. The obtained bronchoalveolar lavage fluid was centrifuged (1500 RPM / 4°C / 10 min), the upper layer was stored at ultracold temperature (-70°C) for cytokine measurement, and cells separated from the bronchoalveolar lavage fluid were treated with ACK (Ammonium-Chloride-Potassium buffer, A10492-01, Gibco, NY, USA) solution for 10 minutes to degrade red blood cells, washed again with phosphate buffer solution, and the total cell count was measured using a hematocytometer.

[0082] The results obtained from the above experiment were recorded as mean ± standard deviation. To determine statistically significant variances, one-way ANOVA was performed using GraphPad Prism 9.5 (GraphPad Software, Inc., Lajolla, CA, USA). If significance was found, Dunnett's multiple comparison test was used. Significance tests were performed when the p-value was <0.05 (*), <0.01 (**), <0.001 (***), or <0.0001 (****).

[0083] The results are shown in Table 2 and Figure 1 below.

[0084]

[0085] [Table 2]

[0086]

[0087] According to Table 2 and Figure 1, the total number of cells in the bronchopulmonary lavage fluid decreased in Examples 2-8 compared to Comparative Examples 2-5. In particular, Examples 3-8 showed a significant decrease in the total number of cells in the bronchopulmonary lavage fluid compared to Comparative Examples 2 and 3-5. Specifically, the total number of cells in the bronchopulmonary lavage fluid decreased when vitamin B5 was administered by inhalation at a dose of 6 mg / kg or more, compared to the induced group and the oral administration group. This confirms that administering vitamin B5 at a certain volume or higher contributes to a reduction in inflammation levels, and that inhalation administration, in particular, exhibits an excellent effect in reducing inflammation levels.

[0088]

[0089] 5. Experimental Example 2: Evaluation of the inhibitory effect on inflammatory cells (neutrophils) in bronchopulmonary lavage fluid.

[0090] The inhibitory effect of bronchopulmonary lavage fluid on inflammatory cells in Examples 1-8 and Comparative Examples 1-5 was evaluated. The evaluation method is as follows.

[0091] After smearing bronchopulmonary lavage fluid onto slides, Diff-Quik (38721, Sysmex, Japan) staining was performed according to the manufacturer's manual. Then, 200 mononuclear and polymorphonuclear cells were counted using a 400x optical microscope. Changes in neutrophil count were confirmed by Diff-Quik staining, and the results obtained from the above experiment were recorded as mean ± standard deviation. Significance testing was performed using the same method as above when the P-value was <0.05 (*), <0.01 (**), <0.001 (***), or <0.0001 (****) or less.

[0092] The results are shown in Table 3 and Figure 2 below.

[0093]

[0094] [Table 3]

[0095]

[0096] As can be seen from Table 3 and Figure 2, in Comparative Example 2, when a fine dust model was induced in experimental animals with PM10D, the number of neutrophils reliably increased, confirming that PM10D increases respiratory inflammation levels. Furthermore, it was confirmed that the number of neutrophils decreased only when administered orally at high doses of 60 mg / kg or more.

[0097] However, when vitamin B5 was administered by inhalation in Examples 1 to 8, a decrease in neutrophil count was observed compared to Comparative Example 2. Furthermore, a superior decrease in neutrophil count was observed in Examples 1 to 8 when administered by inhalation compared to Comparative Examples 3 and 4. A phenomenon of neutrophil reduction similar to that of inhalation administration was observed only when administered at high doses of 60 mg / kg or more, confirming that the composition of the present invention can ensure excellent effects even at low doses. In particular, a significant decrease in neutrophil count was confirmed in Examples 3 to 8.

[0098]

[0099] 6. Experimental Example 3: Confirmation of the effect of immunofluorescence staining indicators in bronchopulmonary lavage fluid.

[0100] The number of neutrophils (CD11b+Gr-1+Siglec-F-) in the bronchopulmonary lavage fluid of Examples 2-6 and 8, and Comparative Examples 1-5, was investigated using immunofluorescence staining indicators. The investigation method is as follows.

[0101] Cells obtained from bronchopulmonary lavage fluid were washed with FACS buffer (PBS with 1.5% FBS added) for cytocellular analysis. Fluorescent substances capable of staining live / dead cells and FACS antibodies recognizing cell surface markers were then diluted in FACS buffer and imprinted on the cells for 20 minutes at 4°C. Information on the fluorescent substances and antibodies used is as follows.

[0102] [Table 4]

[0103]

[0104] After incubation, the cells were washed with FACS buffer and then fixed with fixation buffer (1% PFA and 4% PFA solution diluted in PBS by 1 / 4). Sample acquisition and fluorescence signal detection were performed using a FACS Canto II instrument (BD Biosciences, San Diego, CA, USA), and the results were analyzed using FlowJo (Treestar) software. The number of CD11b+Gr-1+Siglec-F- cells was measured, and the results obtained from the above experiment were recorded as mean ± standard deviation. Significance testing was performed using the same method as above, with a P-value of <0.05(*) or <0.01(**) or less.

[0105] The results are shown in Table 5 and Figure 3 below.

[0106]

[0107] [Table 5]

[0108]

[0109] As can be seen from Table 5 and Figure 3, Example 3 showed approximately 20% suppression compared to Comparative Example 2, and in particular, Example 4 showed 40-60% suppression. Furthermore, compared to Example 8, which involved high-dose, long-duration administration, Examples 4-6, which involved low-dose administration over 20-45 minutes, showed superior suppression results.

[0110]

[0111] 7. Experimental Example 4: Evaluation of the effect on inflammatory factor expression (IL-6)

[0112] The production of the cytokine IL-6 was measured using enzyme-linked immunosorbent assay (ELISA) in bronchopulmonary lavage fluid isolated from Examples 2-6 and 8, and Comparative Examples 1-5. The investigation method is as follows:

[0113] The amount of IL-6 (M6000B, R&D Systems, Minneapolis, USA) in bronchopulmonary lavage fluid was measured using an ELISA kit. Lung lavage fluid obtained from experimental animals was stored in a deep freezer, retrieved, and measured according to the manufacturer's protocol. Absorbance was measured at 450 nm, and the 540 nm measurement value was corrected and used. A SpectraMax i3x (Molecular Devices, San Jose, CA, USA) was used for the measurements.

[0114] The results obtained from the above experiment were recorded as mean ± standard deviation, and significance tests were performed using the same method as above when the p-value was <0.05(*) or <0.01(**).

[0115] The results are shown in Table 6 and Figure 4 below.

[0116]

[0117] [Table 6]

[0118]

[0119] As can be seen from Table 6 and Figure 4, Comparative Example 2, induced with PM10D, showed an increase in the amount of IL-6, an inflammation-related indicator, compared to Comparative Example 1. However, in Examples 3 to 8, where vitamin B5 was administered at 6 to 28 mg / kg, the amount of IL-6 tended to decrease, and this tendency was also observed compared to Comparative Examples 3 to 5, which were administered orally. In particular, Example 4, where 10% vitamin B5 was administered at 10 mg / kg, showed a definite reduction of more than 70%. Furthermore, compared to Example 8, which involved high-dose, long-duration administration, Examples 3 to 6, which involved low-dose administration over 20 to 45 minutes, showed even better reduction results.

[0120]

[0121] Based on the above experimental examples 1 to 4, it is predicted that using the composition for improving respiratory health and treating or preventing respiratory diseases described in the claims will provide a composition that exhibits excellent improvement and therapeutic effects on respiratory inflammation even at low doses.

[0122]

[0123] As described above, although embodiments have been illustrated with limited drawings, a person with ordinary skill in the art can apply various technical modifications and variations based on the above. For example, the described techniques may be performed in a different order than described, and / or the components of the described systems, structures, devices, circuits, etc. may be combined or assembled in a different manner than described, or substituted or replaced by other components or equivalents, and still achieve the desired results.

[0124]

[0125] Therefore, other implementations, other embodiments, and those equivalent to the claims described below also fall within the scope of the claims.

Claims

1. Vitamin B ５ A composition containing as an active ingredient for improving respiratory health and treating or preventing respiratory diseases.

2. The composition for improving respiratory health and treating or preventing respiratory diseases according to claim 1, wherein the composition is applied to inflammation by inhalation or spraying.

3. The inhalation or spray is applied to the oral cavity or nasal cavity, and the composition for improving respiratory health and treating or preventing respiratory diseases is as described in claim 2.

4. The composition for improving respiratory health and treating or preventing respiratory diseases according to claim 2, wherein the inhalation or spraying is applied by an ultrasonic, spray, or fogging device.

5. The composition for improving respiratory health and treating or preventing respiratory diseases according to claim 1, wherein the composition for improving respiratory health and treating or preventing respiratory diseases is a liquid.

6. The composition for improving respiratory health and treating or preventing respiratory diseases according to claim 1, wherein the dosage of the composition for improving respiratory health and treating or preventing respiratory diseases is 1 mg / kg to 30 mg / kg.

7. The aforementioned Vitamin B ５ The concentration of is 2% to 30% by weight relative to the total weight of the composition for improving respiratory health and treating or preventing respiratory diseases, as described in claim 1.

8. The composition for improving respiratory health and treating or preventing respiratory diseases according to claim 1, wherein the administration time of the composition for improving respiratory health and treating or preventing respiratory diseases is 5 minutes to 60 minutes.

9. The respiratory disease comprises at least one selected from the group consisting of allergy, bronchitis, sinusitis, lower respiratory tract infection, bronchiolitis, asthma, chronic obstructive pulmonary disease, rhinitis, pneumonia, emphysema, bronchiectasis, pulmonary fibrosis, cough, sputum, pharyngitis, tonsillitis, and laryngitis, as described in claim 1, for improving respiratory health and treating or preventing respiratory diseases.

10. A pharmaceutical composition for the treatment or prevention of respiratory diseases, comprising a composition for improving respiratory health and treating or preventing respiratory diseases according to any one of claims 1 to 9.

11. A health functional food composition for improving respiratory health or respiratory diseases, comprising a composition for improving respiratory health and treating or preventing respiratory diseases according to any one of claims 1 to 9.

Images